Nuvectra to Participate in Two Upcoming Investor Conferences

PLANO, Texas, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to participate in two upcoming investor conferences.

	Event:	Morgan Stanley 16th Annual Global Healthcare Conference
	Date:	Wednesday, September 12, 2018
	Location:	The Grand Hyatt, New York
	Format:	1x1 Meetings
	Event:	Cantor Fitzgerald Global Healthcare Conference
	Date:	Monday, October 1, 2018
	Time:	4:40 p.m. ET
	Location:	InterContinental New York Barclay Hotel, New York
	Format:	Presentation & 1x1 Meetings

A webcast of the Company’s presentation at the Cantor Fitzgerald Global Healthcare Conference will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.

About Nuvectra Corporation

NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.

Company Contacts:            Nuvectra Corporation         

Walter Berger, COO & CFO (214) 474-3102                      [email protected]     

Investor Contacts:The Ruth Group                  

Tram Bui / Brian Johnston(646) 536-7035 / 7028           [email protected]           

Source: Nuvectra Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA accepts Teva's drug application for Tourette syndrome therapy in children
• Morgan Stanley Upgrades Merck (MRK) to Overweight
• Cornelis and NEC Corporation Expand Collaboration to Advance AI and HPC Infrastructure in Japan